Skip to content

The real-world study on diagnosis and treatment of integrated traditional Chinese and Western medicine treatment for Cardiorenal Syndrome

The real-world study on diagnosis and treatment of integrated traditionalChinese and Western medicine treatment for Cardiorenal Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112812
Enrollment
Unknown
Registered
2025-11-19
Start date
2025-11-19
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiorenal comorbidity

Interventions

prospective cohort:none
retrospective cohort:none

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old, regardless of gender; 2. Individuals meeting any of the following combinations are defined as the "cardiorenal comorbidity" population: Concurrent presence of CKD and CVD; Subsequent development of CVD in patients with CKD (CKD?CVD); New-onset AKI/AKD or CKD following a cardiovascular event (CVD?CKD). 3. In the prospective follow-up population, those who have not yet developed comorbidity involving the other system are also included to observe the incidence process of new-onset "cardiorenal comorbidity" and its predictive factors.

Exclusion criteria

Exclusion criteria: 1. Patients with newly diagnosed primary or secondary tumors within 6 months before enrollment, as well as those undergoing anti-tumor treatment; 2. Severe liver dysfunction (bilirubin or transaminase exceeding twice the upper limit of normal) or severe cerebrovascular disease; 3. Patients with urinary system malformations; 4. Female subjects of childbearing age who are positive for pregnancy test, pregnant, lactating, or those with plans for pregnancy or lactation during the study or who have not taken effective contraceptive measures; 5. Participation in other clinical studies within 1 month before the start of this study; 6. Patients with poor compliance who are deemed unsuitable for enrollment by the researchers.

Design outcomes

Primary

MeasureTime frame
Endpoint events such as rehospitalization and death;

Secondary

MeasureTime frame
Clinical characteristics and disease course information;Dynamic indicators such as blood biochemistry and urine tests (no additional blood samples required);TCM four diagnostic information and syndrome differentiation (conducted in some departments);

Countries

China

Contacts

Public ContactXialian Xu

Zhongshan Hospital, Fudan University

xu.xialian@zs-hospital.sh.cn+86 135 6414 2468

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026